Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Mallinckrodt
Merck
Johnson and Johnson
McKinsey

Last Updated: May 21, 2022

DAYTRANA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Daytrana patents expire, and when can generic versions of Daytrana launch?

Daytrana is a drug marketed by Noven Pharms Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in DAYTRANA is methylphenidate. There are thirty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methylphenidate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Daytrana

A generic version of DAYTRANA was approved as methylphenidate by MYLAN TECH VIATRIS on March 14th, 2022.

  Try it Free

Drug patent expirations by year for DAYTRANA
Drug Prices for DAYTRANA

See drug prices for DAYTRANA

Drug Sales Revenue Trends for DAYTRANA

See drug sales revenues for DAYTRANA

Recent Clinical Trials for DAYTRANA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2/Phase 3
National Cancer Institute (NCI)Phase 2/Phase 3
Matthew O'BrienPhase 4

See all DAYTRANA clinical trials

Paragraph IV (Patent) Challenges for DAYTRANA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DAYTRANA Transdermal System methylphenidate 10 mg/9 hrs 15 mg/9 hrs 20 mg/9 hrs 30 mg/9 hrs 021514 1 2011-04-13

US Patents and Regulatory Information for DAYTRANA

DAYTRANA is protected by three US patents.

Patents protecting DAYTRANA

Device for transdermal administration of drugs including acrylic polymers
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Device for transdermal administration of drugs including acrylic polymers
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Device for transdermal administration of drugs including acrylic based polymers
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DAYTRANA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DAYTRANA

See the table below for patents covering DAYTRANA around the world.

Country Patent Number Title Estimated Expiration
Finland 110994 See Plans and Pricing
Denmark 549489 See Plans and Pricing
Portugal 1037615 See Plans and Pricing
Brazil 9008012 See Plans and Pricing
Finland 121527 See Plans and Pricing
World Intellectual Property Organization (WIPO) 9930694 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
McKinsey
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.